Render Target: STATIC
Render Timestamp: 2024-12-26T11:54:33.093Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-09-30 01:57:33.179
Product last modified at: 2024-12-17T18:51:20.603Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

TWEAK Receptor/Fn14 (E6N2I) Rabbit mAb #27072

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa) 14-17
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:200

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    TWEAK Receptor/Fn14 (E6N2I) Rabbit mAb recognizes endogenous levels of total TWEAK Receptor/Fn14 protein.

    Species Reactivity:

    Human, Mouse, Rat

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly118 within the cytoplasmic region of human TWEAK Receptor/Fn14 protein.

    Background

    The receptor for TWEAK, fibroblast growth factor-inducible 14 (Fn14), is a member of the TNF superfamily of receptors thought to be involved in cell growth, adhesion and migration (1). Its expression is regulated by a number of different growth factors (1,2). Elevated expression is also seen in some cancers including hepatocellular carcinomas (3), glioblastomas (4), and pancreatic cancer (5). The receptor contains a binding site for members of the TNFR-associated factor (TRAF) family that promotes the activation of NF-κB (1,6). Recent studies have suggested some therapeutic potential of TWEAK and its receptor signaling in regards to autoimmunity and cancer treatment (7-9).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.